InsiderTrades

Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-17 · accession 0001470831-26-000182 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-02-18 2026-02-17 BBIO Scott Randal W. Dir M - OptEx $16.75 +10.0K 21.6K +86% +$167.5K
DM 2026-02-18 2026-02-17 BBIO Scott Randal W. Dir S - Sale+OE $75.46 -10.0K 11.6K -46% -$754.6K
D 2026-02-18 2026-02-17 BBIO Scott Randal W. Dir M - OptEx $0.00 -10.0K 31.5K -24% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-17 M A 10,000 $16.75 21,589 D — —
2 Common Common Stock 2026-02-17 S D 1,900 $74.34 19,689 D — — (F2) Represents the weighted average sale price of the shares sold from $73.74 to $74.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3 Common Common Stock 2026-02-17 S D 4,793 $75.57 14,896 D — — (F3) Represents the weighted average sale price of the shares sold from $74.82 to $75.815 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4 Common Common Stock 2026-02-17 S D 3,307 $75.93 11,589 D — — (F4) Represents the weighted average sale price of the shares sold from $75.82 to $76.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5 Derivative Stock Option (Right to Buy) 2026-02-17 M D 10,000 $0.00 31,501 D $16.75 · — to 2033-06-21 10,000 Common Stock (F5) 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.